Estland -
Estlands -
Ravimiamet
dimethyl fumarate gedeon richter gastroresistentne kõvakapsel
gedeon richter plc. - dimetüülfumaraat - gastroresistentne kõvakapsel - 240mg 168tk
Europese Unie -
Estlands -
EMA (European Medicines Agency)
tecfidera
biogen netherlands b.v. - dimetüülfumaraat - hulgiskleroos - immunosupressandid - tecfidera is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).
Europese Unie -
Estlands -
EMA (European Medicines Agency)
dimethyl fumarate mylan
mylan ireland limited - dimetüülfumaraat - sclerosis multiplex, relapsing-remitting - immunosupressandid - dimethyl fumarate mylan is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.
Europese Unie -
Estlands -
EMA (European Medicines Agency)
dimethyl fumarate polpharma
zaklady farmafarmaceutyczne polpharma s.aceutyczne polpharma s.a. - dimetüülfumaraat - sclerosis multiplex, relapsing-remitting - immunosupressandid - dimethyl fumarate polpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.
Estland -
Estlands -
Ravimiamet
dimtruzic gastroresistentne kõvakapsel
sandoz pharmaceuticals d.d. - dimetüülfumaraat - gastroresistentne kõvakapsel - 120mg 14tk
Estland -
Estlands -
Ravimiamet
dimtruzic gastroresistentne kõvakapsel
sandoz pharmaceuticals d.d. - dimetüülfumaraat - gastroresistentne kõvakapsel - 240mg 56tk
Europese Unie -
Estlands -
EMA (European Medicines Agency)
dimethyl fumarate teva
teva gmbh - dimetüülfumaraat - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosupressandid - dimethyl fumarate teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).
Europese Unie -
Estlands -
EMA (European Medicines Agency)
dimethyl fumarate accord
accord healthcare s.l.u. - dimetüülfumaraat - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosupressandid - dimethyl fumarate accord is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).
Europese Unie -
Estlands -
EMA (European Medicines Agency)
skilarence
almirall s.a - dimetüülfumaraat - psoriaas - immunosupressandid - sidumisvastased ravimid on näidustatud mõõduka kuni raskekujulise naastulise psoriaasi ravis täiskasvanutel, kes vajavad süsteemset meditsiinilist ravi.